

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 28<sup>th</sup> February, 2018

**ORDER**

S. O. In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

**Table**

<b>Sl. No.</b>	<b>Name of the Formulation / Brand Name</b>	<b>Strength</b>	<b>Unit</b>	<b>Manufacturer &amp; Marketing Company</b>	<b>Retail Price (Rs.)</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>(5)</b>	<b>(6)</b>
1.	Atorvastatin + Aspirin Capsule (Atchol-ASP 150)	Each hard gelatin capsule contains: Atorvastatin Calcium eq. to Atorvastatin 10mg (as two film -coated tablets of 5 mg each) Aspirin 150mg (as two enteric coated tablets of 75mg each)	1 Capsule	M/s Aristo Pharmaceuticals Pvt. Ltd.	2.10
2.	Nifedipine + Lidocaine Cream (LOXHEAL)	Each 30mg cream contains: Nifedipine IP 0.3 percent w/w, Lidocaine IP 1.5 percent w/w, Imidurea IP (as Preservative) 0.2percent w/w in Cream base	1 GM	M/s Uttaranchal Biotech Ltd. / M/s Neon Laboratories Ltd.	3.14
3.	Pioglitazone + Gliclazide + Metformin Tablet (GLZ Total)	Each film coated tablet contains: Pioglitazone HCL IP eq. to Pioglitazone 15mg, Gliclazide IP 60mg (In modified release form) and Metformin HCL 500mg (extended release form)	1 Tablet	M/s M/s Mascot Health Seris Pvt. Ltd. / M/s Alembic Pharmaceuticals Limited	8.11
4.	Ibuprofen + Paracetamol Tablet (Brufen Plus)	Each film coated tablet contains: Ibuprofen IP 400mg Paracetamol IP 325mg	1 Tablet	M/s Innova Captab Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd.	1.04
5.	Misoprostol Tablet	Each uncoated tablet contains: Misoprostol IP 600mcg (As 1% Misoprostol dispersion)	1 Tablet	M/s Synokem Pharmaceuticals Limited / M/s Bharat Serums and Vaccines Limited	56.81
6.	Glimepiride + Metformin Tablet	Each uncoated bilayered tablet contains: Glimepiride IP 3mg, Metformin Hydrochloride IP 850mg (in Sustained release form)	1 Tablet	M/s Windlas Biotech Ltd. / M/s Intas Pharmaceuticals Limited	7.05
7.	Melphalan + Povidone Injection (Melphalan Injection IP 50mg)	Each vial contains: Melphalan HCL IP eq. to Melphalan 50mg, Povidone IP 20mg and Diluent For Melphalan Injection 10ml	Each Pack	M/s Natco Pharma Ltd	1767.38

		each vial contains Sodium Citrate IP 0.2g Proylene Glycol IP 6ml Ethanol (96%) IP 0.52ml water for Injection			
8.	Trastuzumab Injection	Each Lyophilized vial contains: Trastuzumab 150mg Injection	1 Vial	M/s Cadila Healthcare Limited / M/s Emcure Pharmaceuticals Ltd.	18125.79
9.	Vitamin D3 (Cholecalciferol) (D-RISE SURE)	Each orally Disintegrating Strip contains: Vitamin D3 (Cholecalciferol) IP 60000 IU Orally Disintegrating Strip	1 Orally Disintegrating Strip	M/s Zim Laboratories Limited / M/s USV Limited	24.76

Note:

- (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/187/55/2018/F

F. No. 8(55)/2018/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director